Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database.
OBJECTIVE
Drug interactions resulting in adverse drug reactions (ADRs) represent a major health problem both for individuals and the community. Despite this, limited information is reported in the literature on the drug interaction categories responsible for causing ADRs. In the study reported here, we investigated the drug combinations most frequently co-reported as interacting in the WHO Global Individual Case Safety Report (ICSR) database, VigiBase, and categorised these according to the drug interaction mechanism.


METHODS
Reports in which drug combinations were co-reported as interacting in at least 20 reports in VigiBase during the past 20 years were included in the study. Each drug combination was reviewed in the literature to identify the mechanism of interaction and subsequently classified as pharmacodynamic and/or pharmacokinetic reaction. Report characteristics were also analysed.


RESULTS
A total of 3766 case reports of drug interactions from 47 countries were identified. Of the 123 different drug combinations reported, 113 were described in the literature to interact. The mechanism of the drug interaction was categorised as pharmacodynamic (46 combinations; 41%), pharmacokinetic (28; 25%), a combination of both types (18; 16%) and unidentified (21; 19%). Pharmacodynamic drug interactions primarily concerned pharmacological additive effects, whereas enzyme inhibition was the most frequent pharmacokinetic interaction. The combinations reviewed primarily implicated drugs such as warfarin, heparin, carbamazepine and digoxin.


CONCLUSIONS
Drug interactions reported in globally collected ADR reports cover both pharmacodynamic, specifically additive pharmacological effects, and pharmacokinetic mechanisms primarily accredited to the inhibition of hepatic cytochrome P450 enzymes. These ADR reports often concern serious threats to patients' safety and are particularly related to the use of high risk drugs such as warfarin and heparin.
Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Box 1051, 751 40 Uppsala, Sweden. Johanna.Strandell@who-umc.org
Johanna
J
Strandell
Stina
S
Wahlin
D016907:Adverse Drug Reaction Reporting Systems; D016208:Databases, Factual; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions / Q000145:classification / Q000201:enzymology / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D010599:Pharmacokinetics; D000069437:Pharmacological Phenomena; D060735:Pharmacovigilance; D019338:Polypharmacy; D012306:Risk; D014944:World Health Organization
Clin Pharmacol Ther. 2002 Dec;72(6):685-91
12496749
Drug Saf. 2010 Aug 1;33(8):667-75
20635825
Pharmacol Ther. 2006 Oct;112(1):71-105
16714062
Crit Care Med. 1997 Aug;25(8):1289-97
9267940
Drug Saf. 2007;30(10):883-9
17867725
Ann Pharmacother. 2007 Apr;41(4):674-80
17389673
Ther Drug Monit. 2002 Feb;24(1):91-103
11805729
Br J Clin Pharmacol. 2002 Oct;54(4):349-56
12392581
JAMA. 1995 Jul 5;274(1):29-34
7791255
Drug Saf. 2003;26(6):421-38
12688833
Drug Saf. 2007;30(10):911-8
17867728
Br J Clin Pharmacol. 2008 Jan;65(1):144-6
17635497
PLoS One. 2009;4(2):e4439
19209224
Pharmacotherapy. 2008 Apr;28(4):540-8
18363538
Clin Pharmacol Ther. 2006 Dec;80(6):565-81
17178259
BMJ. 2004 Jul 3;329(7456):15-9
15231615
Am J Cardiol. 2006 Apr 17;97(8A):52C-60C
16581329
Drug Saf. 1994 Feb;10(2):93-102
8011183